Vitro studies have shown that repetitive mutation in EGFR exons 18-25 kinase domain lead to constitutive activation of the EGFR kinase, resulting in over-activation of downstream signaling pathways, promoting cell proliferation and tumor development. The gene discussed is EGFR; the disease is neoplasm.